Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3?
Open Access
- 1 January 2008
- journal article
- research article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 14 (43), 6627-6631
- https://doi.org/10.3748/wjg.14.6627
Abstract
Over the past decade, significant improvements have been made in the treatment of chronic hepatitis C (CHC), especially with the introduction of combined therapy using both interferon and ribavarin. The optimal dose and duration of treatment is still a matter of debate and, importantly, the efficacy of this combined treatment varies with the viral genotype responsible for infection. In general, patients infected with viral genotypes 2 or 3 more readily achieve a sustained viral response than those infected with viral genotype 1. The introduction of a pegylated version of interferon in the past decade has produced better clinical outcomes in patients infected with viral genotype 1. However, the published literature shows no improvement in clinical outcomes in patients infected with viral genotypes 2 or 3 when they are treated with pegylated interferon as opposed to non-pegylated interferon, both given in combination with ribavarin. This is significant because the cost of a 24-wk treatment with pegylated interferon in less-developed countries is between six and 30 times greater than that of treatment with interferon. Thus, clinicians need to carefully consider the cost-versus-benefit of using pegylated interferon to treat CHC, particularly when there is no evidence for clinically measurable benefits in patients with genotypes 2 and 3 infections.Keywords
This publication has 55 references indexed in Scilit:
- Insulin Resistance Among Patients With Chronic Hepatitis C: Etiology and Impact on TreatmentClinical Gastroenterology and Hepatology, 2008
- Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus‐infected and hepatitis C virus‐cleared patientsLiver International, 2008
- Sustained virological response based on rapid virological response in genotype-3 chronic hepatitis C treated with standard interferon in the Pakistani populationWorld Journal of Gastroenterology, 2008
- Mechanisms of Disease: HCV-induced liver injuryNature Clinical Practice Gastroenterology & Hepatology, 2007
- Hepatitis C Virus Stabilizes Hypoxia-Inducible Factor 1α and Stimulates the Synthesis of Vascular Endothelial Growth FactorJournal of Virology, 2007
- Hepatitis C Virus Induces Proteolytic Cleavage of Sterol Regulatory Element Binding Proteins and Stimulates Their Phosphorylation via Oxidative StressJournal of Virology, 2007
- A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis CGut, 2007
- Hepatitis CNature, 2005
- Treatment of hepatitis C virus infection in patients of northern IndiaJournal of Gastroenterology and Hepatology, 2004
- Genotype distribution of hepatitis C virus in São Paulo, Brazil: Rare subtype foundHepatology, 1999